Conatus Pharmaceuticals, Inc.
Records under this name other than the patents Conatus Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Conatus Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,790,989 | Inhibitors of the ICE/ced-3 family of cysteine proteases Term ended Ended no later than Jan 26, 2021 · From the USPTO record | Term ended | Ended no later than Jan 26, 2021 | From the USPTO record |
| US 6,762,045 | Membrane derived caspase-3, compositions comprising the same and methods of use therefor Term ended Term ended Nov 20, 2020 · From the USPTO record | Term ended | Term ended Nov 20, 2020 | From the USPTO record |
| US 7,053,056 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Term ended Term ended Apr 8, 2020 · From the USPTO record | Term ended | Term ended Apr 8, 2020 | From the USPTO record |
| US 7,183,260 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Term ended Term ended Oct 23, 2018 · From the USPTO record | Term ended | Term ended Oct 23, 2018 | From the USPTO record |
| US 6,197,750 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Term ended Term ended Oct 22, 2018 · From the USPTO record | Term ended | Term ended Oct 22, 2018 | From the USPTO record |
| US 6,544,951 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases Term ended Ended no later than Oct 22, 2018 · From the USPTO record | Term ended | Ended no later than Oct 22, 2018 | From the USPTO record |
| US 6,824,991 | Human bad polypeptides, encoding nucleic acids and methods of use Term ended Term ended Jun 2, 2018 · From the USPTO record | Term ended | Term ended Jun 2, 2018 | From the USPTO record |
| US 6,693,096 | Treatment of inflammation-associated disorders using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors Term ended Term ended Nov 29, 2017 · From the USPTO record | Term ended | Term ended Nov 29, 2017 | From the USPTO record |
| US 6,610,683 | Treatment of infectious disease using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors Term ended Term ended Oct 13, 2017 · From the USPTO record | Term ended | Term ended Oct 13, 2017 | From the USPTO record |
| US 6,200,969 | Inhibition of apoptosis using interleukin-1.beta.-converting enzyme (ICE)/CED-3 family inhibitors Term ended Term ended Sep 12, 2017 · From the USPTO record | Term ended | Term ended Sep 12, 2017 | From the USPTO record |